TY - JOUR
T1 - Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation
AU - Biernacki, Melinda A.
AU - Tai, Yu Tzu
AU - Zhang, Guang Lan
AU - Alonso, Anselmo
AU - Zhang, Wandi
AU - Prabhala, Rao
AU - Zhang, Li
AU - Munshi, Nikhil
AU - Neuberg, Donna
AU - Soiffer, Robert J.
AU - Ritz, Jerome
AU - Alyea, Edwin P.
AU - Brusic, Vladimir
AU - Anderson, Kenneth C.
AU - Wu, Catherine J.
N1 - Copyright:
Copyright 2013 Elsevier B.V., All rights reserved.
PY - 2012/3/29
Y1 - 2012/3/29
N2 - Targets of curative donor-derived graft-versus-myeloma (GVM) responses after allogeneic hematopoietic stem cell transplantation (HSCT) remain poorly defined, partly because immunity against minor histocompatibility Ags (mHAgs) complicates the elucidation of multiple myeloma (MM)-specific targets. We hypothesized that syngeneic HSCT would facilitate the identification of GVM-associated Ags because donor immune responses in this setting should exclusively target unique tumor Ags in the absence of donor-host genetic disparities. Therefore, in the present study, we investigated the development of tumor immunity in an HLA-A0201+ MM patient who achieved durable remission after myeloablative syngeneic HSCT. Using high-density protein microarrays to screen post-HSCT plasma, we identified 6 Ags that elicited high-titer (1:5000-1:10 000) Abs that correlated with clinical tumor regression. Two Ags (DAPK2 and PIM1) had enriched expression in primary MM tissues. Both elicited Ab responses in other MM patients after chemotherapy or HSCT (11 and 6 of 32 patients for DAPK2 and PIM1, respectively). The index patient also developed specific CD8+ T-cell responses to HLA-A2-restricted peptides derived from DAPK2 and PIM1. Peptide-specific T cells recognized HLA-A2+ MM-derived cell lines and primary MM tumor cells. Coordinated T- and B-cell immunity develops against MM-associatedAgs after syngeneic HSCT. DAPK1 and PIM1 are promising target Ags for MM-directed immunotherapy.
AB - Targets of curative donor-derived graft-versus-myeloma (GVM) responses after allogeneic hematopoietic stem cell transplantation (HSCT) remain poorly defined, partly because immunity against minor histocompatibility Ags (mHAgs) complicates the elucidation of multiple myeloma (MM)-specific targets. We hypothesized that syngeneic HSCT would facilitate the identification of GVM-associated Ags because donor immune responses in this setting should exclusively target unique tumor Ags in the absence of donor-host genetic disparities. Therefore, in the present study, we investigated the development of tumor immunity in an HLA-A0201+ MM patient who achieved durable remission after myeloablative syngeneic HSCT. Using high-density protein microarrays to screen post-HSCT plasma, we identified 6 Ags that elicited high-titer (1:5000-1:10 000) Abs that correlated with clinical tumor regression. Two Ags (DAPK2 and PIM1) had enriched expression in primary MM tissues. Both elicited Ab responses in other MM patients after chemotherapy or HSCT (11 and 6 of 32 patients for DAPK2 and PIM1, respectively). The index patient also developed specific CD8+ T-cell responses to HLA-A2-restricted peptides derived from DAPK2 and PIM1. Peptide-specific T cells recognized HLA-A2+ MM-derived cell lines and primary MM tumor cells. Coordinated T- and B-cell immunity develops against MM-associatedAgs after syngeneic HSCT. DAPK1 and PIM1 are promising target Ags for MM-directed immunotherapy.
UR - http://www.scopus.com/inward/record.url?scp=84859332810&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859332810&partnerID=8YFLogxK
U2 - 10.1182/blood-2011-11-388926
DO - 10.1182/blood-2011-11-388926
M3 - Article
C2 - 22267603
AN - SCOPUS:84859332810
VL - 119
SP - 3142
EP - 3150
JO - Blood
JF - Blood
SN - 0006-4971
IS - 13
ER -